|
MechanismIL-11RA antagonists |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor that is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and TED. This study is a four-part trial consisting of Parts A, B, C and D.
The primary objective of this study is to evaluate the safety and tolerability of LASN01, and the secondary objective is to evaluate the preliminary efficacy, immunogenicity, and pharmacokinetics of single and multiple doses of LASN01 in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD) or Thyroid Eye disease (TED).
Please note that the Phase 1 (single and multiple ascending dose, SAD/MAD) portion in healthy subjects is completed and the Phase 2a portion in patients is no longer recruiting.
100 Clinical Results associated with Lassen Therapeutics 1 Pty Ltd.
0 Patents (Medical) associated with Lassen Therapeutics 1 Pty Ltd.
100 Deals associated with Lassen Therapeutics 1 Pty Ltd.
100 Translational Medicine associated with Lassen Therapeutics 1 Pty Ltd.